Source: Viemed Healthcare Inc.
  • Viemed Healthcare (VMD) has announced a share repurchase program on Nasdaq
  • Viemed may repurchase up to 1,984,014 common shares
  • Daily purchases will be limited to 25 per cent of the average daily trading volume on Nasdaq
  • Shares purchased by the company will be cancelled and returned to treasury
  • Viemed provides in-home medical equipment and post-acute respiratory healthcare services in the United States
  • Viemed Healthcare Inc. (VMD) opened trading at C$4.58 per share

Viemed Healthcare (VMD) has announced a share repurchase program on Nasdaq.

Under the share repurchase program, Viemed may repurchase up to 1,984,014 common shares ‎representing approximately 5 per cent of the total issued and outstanding common shares as of March ‎4‎, 2022.‎

Daily purchases will be limited to 25 per cent of the average daily trading volume on Nasdaq for the four calendar weeks preceding the date of purchase.

“Based on the strength of our balance sheet and excess free cash flow, we believe we are well positioned to execute on this attractive opportunity to increase shareholder value while maintaining resources to fund our operations and continued growth,” said Casey Hoyt, Viemed CEO.

“This program demonstrates our confidence in the Viemed business and our commitment to creating long term sustainable value for our shareholders.”

All shares will be purchased through the facilities of Nasdaq. The company may discontinue its purchases at any time.‎ Shares purchased by the company will be cancelled and returned to treasury.

Viemed provides in-home medical equipment and post-acute respiratory healthcare services in the United States.

Viemed Healthcare Inc. (VMD) opened trading at C$4.58 per share.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.